Learn More
Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal and other end-organ damage. We originally conducted two phase 2 studies (26 weeks and 1 year) evaluating eculizumab, a terminal complement inhibitor, in patients with(More)
The authors would like to thank the Ford Foundation for its generosity. Without such funding, ISOFI would not have transformed the lives, organizations and programs as was observed over the past two years. Special thanks goes to Sarah Costa for having a vision and translating it into action. Thanks also for the insights of Susan Wood and Roshmi Goswami,(More)
  • 1